Our Pipeline

LondonPharma has drug development programmes under way in various indications including cancer (LON002 in Phase lb/lla clinical trials), Lyme disease, blood-fluke, erectile dysfunction, pain, addiction and nausea using its repurposing expertise for sublingual delivery.

Updated: 13/11/14

Print this page